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ver a century ago, numerous case reports des-
cribed the onset of mood and behavioral disorders in
temporal association with altered reproductive function,
as well as the dramatic remission of mood and behav-
ioral symptoms following the resumption of normal
menstruation. Indeed, treatment strategies frequently
included efforts to either normalize menstruation or
remove the reproductive organs of women with mental
illness.Although interest in reproductive endocrine ther-
apies for mood disorders has persisted throughout the
past century, the specific role, if any, that reproductive
endocrine interventions should play in the treatment of
mood disorders is still unclear.
In this article, we will describe the recent history of
reproductive endocrine therapies for mood disorders,
review the biology of gonadal steroids that may be rele-
vant to mood regulation, discuss the current role for
reproductive endocrine therapies in both reproductive
endocrine–related mood disorders and classical mood
disorders,and review theories about the mechanisms of
action of gonadal steroids in the treatment of these con-
ditions. Finally, we will discuss the potential future role
of these and related compounds in the treatment of
mood disorders.
Background
The 19th century medical literature contained several
presumptions about the pathophysiology of mood dis-
orders in women largely based on anecdotal observa-
tions of reproductive endocrine dysfunction (eg, amen-
orrhea) in psychiatrically ill women.
1-5 These inferences,
in turn, were translated into therapeutics.Thus, numer-
ous reports also documented the beneficial effects on
mood and behavior associated with medical or surgical
manipulations of a woman’s reproductive function.
6-9 In
addition to their interest in the role of reproductive func-
tion in psychiatry, medical researchers in the late 19th
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There has been a century-long view in medicine that
reproductive function in both men and women is inti-
mately involved with mood regulation. The 19th centu-
ry witnessed a proliferation of medical reports docu-
menting beneficial effects on mood and behavior after
medical or surgical manipulations of women’s reproduc-
tive function. More recently, the results of several studies
suggest that gonadal steroids do regulate mood in some
women. Thus, there is considerable interest in the poten-
tial role of reproductive therapies in the management of
depressive illness, including both classical and reproduc-
tive endocrine–related mood disorders. Future studies
need to determine the predictors of response to hor-
monal therapies compared with traditional antidepres-
sant agents, and to characterize the long-term safety and
benefits of these therapies.
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century also developed an interest in glandular secre-
tions and factors that potentially modify physiology.
10
Early experiments in humans with preparations derived
from animal glands including thyroid, adrenal, ovary,
testes,and spleen provided the directions for the devel-
oping fields of endocrinology and immunology. In his
seminal lecture in 1889,Brown-Séquard
11 not only orig-
inated the formal study of endocrinology,but he reported
the potential psychotropic effects of gonadal secretions.
His description of the invigorating effects of testicular
extracts resulted in a brief but widespread use of these
compounds (as well as other interventions intended to
increase the body’s testicular or seminal fluid levels) in
a variety of therapeutic settings.
12-14 In addition to
extracts of both testes and ovaries, investigators exper-
imented with extracts of the thyroid and adrenal glands
in psychiatric patients.
10 This interest in thyroid and
adrenal extracts enjoyed more enduring success with the
recognition of their beneficial effects in the treatment of
myxedema and Addison’s disease, respectively.
15
However, the widespread use of gonadal extracts ulti-
mately met with criticism due to some disappointing
results and the realization that these extracts were not
the “fountain of youth.”Their subsequent clinical use
was largely restricted to the treatment of menopause-
related hot flushes (ovarian extracts).
16 Nonetheless,the
observation that ovarian extracts inhibited ovulation in
rabbits was sufficient to maintain medical interest in the
potential role of gonadal extracts for the control of
human fertility.
17
Efforts to improve techniques of extraction and purifi-
cation of biologically active substances from the gonads
were fueled by the hope that factors regulating repro-
ductive function would be identified. By the late 1920s
and early 1930s through the efforts of Allen and Doisy,
18
Corner and Allen,
19 as well as others, many gonadal
steroids were isolated and characterized including
estrone,estradiol,progesterone,and several androgens.
Moreover, during the next 10 years, chemists identified
modifications of the steroids that could alter their
absorption (eg,acetylation) and potency (eg,addition of
ethinyl group or removal of C-19 methyl group).These
findings initiated a resurgence in the medical use of
gonadal steroids.
20-23 Estrogen replacement therapy
(ERT) was used to treat menopausal symptoms in the
1930s, and oral contraceptives (OCs) were developed
and first approved (ie, Enovid
®) by the Food and Drug
Administration (FDA) in 1960.The use of exogenous
gonadal steroids in women was once again widespread,
and several papers were published reporting the thera-
peutic benefits of these compounds in involutional
melancholia,
24,25 premenstrual syndrome (PMS),
26,27 and
postpartum depression (PPD).
28-30 However, their wide-
spread usage was restricted after reports in the 1970s of
increased rates of endometrial cancer secondary to
unopposed ERT and increased rates of thrombosis and
pulmonary emboli in women taking OCs.
23,31 More
recently, gonadal steroid therapy has gained popularity
due in part to the reports of the enhanced safety of both
ERT and OCs and the reported beneficial/disease pro-
tective effects of gonadal steroids on multiple organ sys-
tems including the musculoskeletal,cardiovascular,and
central nervous systems.
32-36 The discovery of several
other factors involved in the control of reproduction also
led to new drug development. The decapeptide
gonadotropin-releasing hormone (GnRH) was isolated
and sequenced in the 1970s, and the observation that
continuous GnRH infusion resulted in the downregula-
tion of pituitary GnRH receptors led to the develop-
ment of several GnRH agonists.
37,38These agonists were
used to suppress reproductive endocrine function in a
variety of medical conditions including hormone-depend-
ent cancers and endometriosis.
39,40 In combination with
gonadal steroids, preparations of GnRH agonists pro-
vided physicians with a strategy to control reproductive
function and regulate the exposure to specific gonadal
steroids without resorting to surgery.Thus physicians
could selectively eliminate and/or replace reproductive
factors considered to be the potential source of a med-
ical or psychiatric problem.
Selected abbreviations and acronyms
BDNF brain-derived neurotrophic factor
CREB cyclic adenosine monophosphate response
element-binding (protein)
DHEA dehydroepiandrosterone
ECT electroconvulsive therapy
ERT estrogen replacement therapy
FSH follicle-stimulating hormone
GnRH gonadotropin-releasing hormone
5-HT serotonin (5-hydroxytryptamine)
OC oral contraceptive
PMS premenstrual syndrome 
PPD postpartum depression
SSRI selective serotonin reuptake inhibitor213
Could gonadal steroids be involved in 
mood regulation?
Results from animal studies demonstrate that gonadal
steroids influence several of the neuroregulatory systems
thought to be involved in both the pathophysiology of
affective disorders and the efficacy of antidepressant
therapies.
41-45 In some, but not all,
46 experimental para-
digms, estradiol has been observed to inhibit serotonin
reuptake transporter (SERT) mRNA
47 and decrease
activity at serotonin (5-hydroxytryptamine) 5-HT1A
receptors,
48,49 consistent with some reported actions of
antidepressants on serotonergic system function.
Moreover,in one study estradiol and testosterone facil-
itated imipramine-induced downregulation of 5-HT2
receptors in the rat frontal cortex.
50 In addition to clas-
sic neurotransmitter systems, several candidate neural
signaling systems have been identified as potential medi-
ators of the therapeutic actions of antidepressants and
electroconvulsive therapy (ECT) (eg, cyclic adenosine
monophosphate [cAMP] response element-binding
[CREB] protein and brain-derived neurotrophic factor
[BDNF])
51-54 based on observations that these systems
are modulated by a range of therapies effective in
depression (eg, serotonergic and noradrenergic agents
and ECT) and exhibit a pattern of change consistent
with the latency to therapeutic efficacy for most antide-
pressants.
55 For example, antidepressants increase the
expression and activity of CREB in certain brain regions
(eg,hippocampus)
56 and regulate (in a brain region–spe-
cific manner) activity of genes with a cAMP response
element.
55 Genes for BDNF and its receptor trkB have
been proposed as potential targets for antidepressant-
related changes in CREB activity.
55,57 Similarly,estradiol
has been reported to influence many of these same neuro-
regulatory processes.Specifically,ovariectomy has been
reported to decrease,and estradiol increase,BDNF lev-
els in the forebrain and hippocampus.
58,59 Estrogen also
increases CREB activity
60,61 and trkA
62 in the rat brain.
In contrast,an estradiol-induced decrease in BDNF has
been reported to mediate estradiol’s regulation of den-
dritic spine formation in hippocampal neurons.
63 Thus,
the therapeutic potential of gonadal steroids in depres-
sion is not only suggested by their widespread actions on
neurotransmitter systems, but also by certain neuro-
regulatory actions shared by both estrogen and tradi-
tional therapies for depression (ie, antidepressants,
ECT).
Gonadal steroids in the treatment of 
mood disorders
Reproductive endocrine–related mood disorders
Reproductive endocrine–related mood disorders refer
to depressive-like disorders in which the appearance of
mood disturbances occurs in temporal association with
a change in reproductive function, and includes mood
disorders occurring in association with the luteal phase
of the menstrual cycle, the postpartum, and the peri-
menopause.Given the apparent association between the
onset of mood disturbance and the change in reproduc-
tive function, these conditions have been suggested to
develop secondary to some abnormality in ovarian hor-
mone secretion, and reproductive therapies have been
used in an attempt to correct the presumed endocrine
anomaly.
64
Premenstrual syndrome
PMS is a condition characterized by cyclic changes in
symptoms (including irritability,sadness,and anxiety) that
interfere with daily function and are confined to the luteal
phase of the menstrual cycle, with symptom remission
occurring within a few days of the onset of menses.
65 No
diagnosis-related differences in reproductive hormones
have been consistently observed during the luteal phase
that would distinguish a woman with PMS from a woman
without PMS.
66 Despite the lack of evidence of ovarian
dysfunction in women with PMS,the association of PMS
symptoms with the luteal phase of the menstrual cycle
perpetuated clinicians’ views that an abnormality of cor-
pus luteum function caused PMS. Thus, multiple trials
were conducted involving the administration of proges-
terone or progestin in women with PMS.
67 However,the
widespread use of progesterone in women with PMS was
considerably diminished by the results of several recent
studies:first,two large double-blind,placebo-controlled
trials of natural progesterone (both suppository and oral
forms) definitively demonstrated the lack of efficacy of
progesterone compared with placebo in PMS.
68,69 Second,
a study employing a progesterone receptor antagonist,
RU-486,with or without human chorionic gonadotropin,
demonstrated that the normal symptoms of PMS could
occur independently of the luteal phase of the menstru-
al cycle
70 and,therefore,a luteal phase abnormality as a
cause of PMS was no longer tenable.
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The belief that PMS reflected a disturbance in ovarian
function led to several trials of OCs to suppress or reg-
ulate ovarian function in this condition. Earlier cross-
sectional studies suggested that women using OCs expe-
rienced fewer PMS symptoms than nonusers.
71-73
However,studies also reported the opposite,
74 and most
results demonstrated that women on OCs reported
fewer physical symptoms (ie, breast pain, bloating), but
did not report fewer or less severe mood symptoms than
nonusers.
75-77 In fact, similar prevalence rates of cyclic
mood symptoms regardless of OC use were prospec-
tively documented by Sveindottir et al,
78 with 2% to 6%
of women meeting criteria for severe PMS in both OC
users and nonusers.Moreover,observations suggest that
the severity of mood symptoms do not vary with differ-
ent preparations of OCs (eg,monophasic versus triphas-
ic)
79,80;however,one study did observe that the progestin
desogestrel (reported to have less androgenic activity)
was associated with fewer mood symptoms than levo-
norgestrel.
81 Despite similar prevalence rates of negative
mood symptoms in OC users and nonusers,some clinic-
based studies suggested that a subgroup of women with
PMS reported an improvement in mood symptoms
while on OCs.
82-87 None of the recent controlled trials of
OCs in PMS have observed significant improvement (or
worsening) in mood symptoms relative to placebo.
88-90
However,these trials did observe significant reductions
in symptom severity on OCs compared with placebo for
some physical and behavioral symptoms, including loss
of libido,
89 breast pain, and bloating,
88 and increased
appetite and food cravings.
90Thus,neither cross-section-
al studies nor controlled trials support a role for any for-
mulation of OCs (tested to date) in the treatment of
PMS.
Investigators have also examined the efficacy in PMS of
estradiol (without the progestin contained in OCs) or
testosterone.Trials of supraphysiologic doses of estradi-
ol with or without testosterone have documented bene-
ficial effects compared with placebo in women with
PMS.
91-93 Preliminary reports suggest that lower (more
physiologic) doses of testosterone alone may also be
effective in the treatment of PMS.
94-96 Lower doses of
estrogen,however,are no more effective than placebo
97
and,therefore,it is possible that the therapeutic benefits
of the higher dose estrogens are secondary to the sup-
pression of ovulation.
93 Nevertheless, one cannot infer
the efficacy of these compounds to be secondary to
ovarian suppression alone, given the lack of efficacy of
OCs,which also inhibit ovulation,and the reported effi-
cacy of compounds such as danazol
98 when administered
after ovulation in at least one study.
99
Several open trials of ovarian suppression,induced sur-
gically or medically,have reported the beneficial effects
of this strategy in the treatment of PMS.
100-107 Most,
108-111
but not all,
112,113 placebo-controlled trials of GnRH agon-
ists (eg, leuprolide acetate) in PMS have reported the
therapeutic efficacy of GnRH agonist–induced ovarian
suppression compared with placebo.We observed sig-
nificant reductions in PMS symptom severity during
leuprolide treatment for all symptoms measured.
114 In
many of the trials, the degree of individual response to
GnRH agonist varied considerably, despite evidence of
a beneficial response to ovarian suppression on a group
basis. We observed a response rate of approximately
60% employing relatively conservative criteria (ie, the
absence within a 2-month time period of 2-weekly mean
scores on anxiety,depression,or irritability greater than
2.5 on a 6-point scale).
114 Similarly,Freeman et al reported
that 67% of women with PMS responded to GnRH ago-
nist–induced ovarian suppression.
109 Response rates did
not differ depending on the presence or absence of a
past history of affective disorder in our sample of
women with PMS. However, Freeman et al observed
that the presence of persistent depressive symptoms
throughout the menstrual cycle was associated with non-
response to GnRH agonists.
109 The reported response
rates to selective serotonin reuptake inhibitors (SSRIs)
in women with PMS (40%–60%)
115-122 appear similar to
the rates observed in trials of GnRH agonists. Thus,
although the majority of studies would support the
short-term use of GnRH agonists or SSRIs in this con-
dition, symptomatic response is not uniform even to
complete ovarian suppression.Moreover,it has not been
determined whether the group of women with PMS who
are responsive to SSRIs differs from those responsive to
hormonal therapies.The factors that predict response to
both therapies need to be identified,and these data may
reveal further information about the pathophysiology of
PMS.
The possibility that PMS reflects an abnormal mood and
behavioral response to normal changes in ovarian steroid
secretion has been suggested by several studies.
102,114,123-126
We observed the precipitation of typical PMS symptoms
after the administration of physiologic doses of either
estradiol or progesterone in a group of women whose
PMS symptoms were otherwise eliminated by ovarian
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suppression with a GnRH agonist.
114 Asymptomatic
women who had no history of PMS undergoing the same
hormonal manipulations showed no disturbance of
mood during either hypogonadal conditions or hor-
monal addback.It would appear,therefore,that women
with PMS are differentially sensitive to the mood-per-
turbing effects of gonadal steroids, as similar steroid
manipulations in women without a history of PMS were
without effect on mood.
The efficacies of both GnRH agonists and high-dose
estrogen therapy in the treatment of PMS and the lack
of efficacy of most OCs suggest that continuous steady-
state levels of gonadal steroids may prevent the cyclic
symptoms of PMS. Thus, the prolonged use of active
OCs continuously may provide an additional treatment
for some women with PMS. Nevertheless, typical PMS
symptoms would be predicted to emerge if hormones
are withdrawn and then readministered.Trials of steady-
state hormonal therapy are underway and may lead to
an effective treatment for PMS as an alternative to tra-
ditional SSRIs.
Perimenopausal depression
Perimenopausal depression is a condition defined by the
onset of depression at middle age in association with the
onset of menstrual cycle irregularity or amenorrhea.
Perimenopausal reproductive status is confirmed by the
presence of menstrual cycle irregularity (or amenorrhea
of less than 1 year’s duration) and hormonal evidence of
ovarian dysfunction.This latter criterion has been oper-
ationalized to include either a single elevated plasma fol-
licle-stimulating hormone (FSH) level or more persis-
tent elevations of plasma FSH levels (eg, three out of
four ≥14 IU/L).
127 The Diagnostic and Statistical Manual
of Mental Disorders 4th edition (DSM-IV)
128 includes
neither perimenopausal depression as a distinct mood
disorder nor the perimenopause as a course specifier (as
it does the postpartum period).Perimenopausal depres-
sions may not be distinguished from major depressive
disorder on the basis of phenomenology,course,family,
or personal history of mood disorder,but they do appear
to be distinct in their treatment response characteristics;
specifically, they are responsive to ERT in contrast to
depressions either before or after the perimenopausal
phase.
129,130
Despite the coincident timing of the onset of depression
and the perimenopause, there has been no consistent
evidence suggesting that perimenopausal depressed
women can be distinguished from asymptomatic peri-
menopausal women on the basis of abnormalities of
ovarian estrogens or androgens.
131 Nonetheless, there
have been several therapeutic trials of ERT in peri-
menopausal and postmenopausal women with depres-
sion.
Controlled studies employing synthetic forms of estro-
gen in the treatment of depression have yielded mixed
results. Estrogen has been reported to improve mood
(albeit inconsistently)
132-134 in the following samples: (i)
perimenopausal and postmenopausal women reporting
depressive symptoms
135-137; (ii) postmenopausal women
with depression unresponsive to traditional antidepres-
sant therapy
138; and (iii) nondepressed menopausal
women not experiencing hot flushes.
139
We examined the therapeutic efficacy of estradiol
replacement in 34 women (approximately half of whom
had no prior history of depression) with perimenopausal
depression under double-blind,placebo-controlled con-
ditions.
129 After 3 weeks of estradiol, depression rating
scale scores were significantly decreased compared with
baseline scores and significantly lower than scores in the
women receiving placebo.A full or partial therapeutic
response was seen in 80% of subjects on estradiol and in
22% of those on placebo, consistent with the observed
effect size in a recent meta-analysis of studies examining
estrogen’s effects on mood.
140The therapeutic response to
estrogen was observed in both major and minor depres-
sion as well as in women with and without hot flushes.
Finally,neither baseline nor posttreatment estradiol lev-
els predicted therapeutic response.These data suggest
that estrogen’s effect on depression is not solely a pro-
duct of its ability to reduce the distress of hot flushes.
Our findings are consistent with data from Montgomery
et al
135 and Saletu et al
136 suggesting the beneficial effects
of estrogen on mood in perimenopausal women report-
ing depressive symptoms.Two recent studies, by Soares
et al
130 and Morrison et al (personal communication)
have extended these observations. First, Soares et al
reported a significant and beneficial effect of ERT com-
pared with placebo in women with perimenopause-
related major depression (as defined by the Primary
Care Evaluation of Mental Disorders [PRIME-MD])
141
and,additionally,reported that baseline plasma estradi-
ol levels did not predict response to estrogen treat-
ment.
130 Second, Morrison et al observed that estrogen
was no more effective than placebo in postmenopausal
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depressed women in contrast to previous results in peri-
menopausal women.These data emphasize that the stage
of reproductive senescence may predict response to estro-
gen,as originally reported by Appleby et al.
142Thus,peri-
menopausal women who are undergoing changes in repro-
ductive function may be more responsive to estrogen than
postmenopausal women whose hormonal changes have
long since stabilized.
Postpartum depression
PPD is defined in the DSM-IV
128 as the onset of a depres-
sive disorder within 4 weeks after delivery.The symptoms
of depression during the postpartum are not distinct
from depressions occurring at other periods of life, and
the temporal association of symptoms with the postpar-
tum period is the critical diagnostic feature, similar to
perimenopausal depression. PPDs are not associated
with an abnormality of reproductive function
143;nonethe-
less, women with a history of PPD display an abnormal
mood response to changes in reproductive hormones
simulating endocrine events occurring at delivery.
144
Despite the absence of endocrine abnormalities in this
condition, there has been interest in whether supple-
menting reproductive endocrine function during the
immediate postpartum could prevent or diminish depres-
sion.
Open studies of progesterone for the treatment of PPD
were conducted by Dalton,
145 who reported a reduced
recurrence rate of postnatal depression in women using
prophylactic progesterone compared with untreated
women.
146 Nonetheless, as with studies of progesterone
in PMS, the absence of controlled trials examining the
efficacy of progesterone in PPD limited the utility of
Dalton’s observations.In fact,one double-blind,placebo-
controlled study of 180 postpartum women,treated with
either norethisterone enanthate or placebo, showed an
increased risk of developing depressive symptoms fol-
lowing treatment with norethisterone.
147 Thus, as with
PMS, current evidence does not support a role for pro-
gesterone in the treatment of PPD.
Similar to earlier reports of progesterone’s efficacy, an
open trial in women at risk for puerperal psychosis
demonstrated that high-dose estrogen treatment resulted
in a lower than expected 1-year relapse rate (9% com-
pared with an expected 35%–60% without prophylax-
is).
148 Varying doses of estrogen (Premarin
® ranging in
dose from 0.625 to 10 mg per day or IV estradiol 25 mg
every 8 hours) were administered immediately postpar-
tum and then tapered over 4 weeks.It was suggested that
estrogen administration could attenuate the rapid puer-
peral drop in estradiol levels,thereby reducing the nega-
tive impact of the postpartum “estrogen withdrawal
state”on mood.In a follow-up study,Gregoire et al
149 test-
ed the suggestion that estradiol withdrawal caused PPD
in a double-blind,placebo-controlled study of estradiol in
61 women who developed major depression within 3
months of delivery.Eighty percent of the patients receiv-
ing estrogen patch experienced a significant reduction in
depression severity after 3 months of treatment, com-
pared with 31% of the placebo-treated group.Reductions
in mood symptoms on estrogen therapy were observed in
women regardless of concurrent antidepressant use,and
estrogen’s antidepressant effects were rapid and observed
after 2 to 3 weeks of treatment.A similar rapid response
to estradiol was also recently reported in an open-label
trial of sublingual estradiol,
150 similar to the timing of the
response to estradiol in perimenopausal depression.
Classical mood disorders
In contrast to reproductive endocrine–related mood dis-
orders, classical mood disorders, with few exceptions,
have a more tenuous relationship with reproductive
endocrine change.Several relationships have been pro-
posed to explain reported observations.First,alterations
in reproductive function may modulate the course or
appearance of mood disorders. For example, investiga-
tors have described the menstrual cycle–related exacer-
bation or modulation of the symptoms of depressive and
anxiety disorders, as well as bipolar illness.
151 It is possi-
ble, therefore, that reproductive therapies would influ-
ence the course of these conditions.
152 Indeed, clinical
anecdotes describe the therapeutic benefits of ovarian
suppression with GnRH agonists in women with men-
strual cycle–entrained rapid cycling bipolar illness.
Second, the hormonal accompaniments of aging, some
of which involve reproductive hormones,may influence
the onset of depression.Late- and midlife-onset depres-
sions occur in the context of declining adrenal androgen
secretion and reproductive senescence, and, therefore,
the replacement of these reproductive hormones in late-
and midlife-onset depressions may have a role in their
treatment.
153-155 Finally,gonadal steroids may modify the
treatment response characteristics of subjects treated
with conventional antidepressants.Some
156,157 but not all
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studies have reported that the administration of estro-
gen enhances the therapeutic response to certain psy-
chotropic agents including SSRIs.Additionally, altered
reproductive endocrine function may result in disturb-
ances in certain target symptoms,such as loss of libido,
159
that occur in association with depression, but are not
part of its presentation. Such symptoms, for example,
may be responsive to androgen replacement but not
antidepressant therapy.Similarly,androgen therapy may
be effective in treating loss of libido occurring as a side
effect of antidepressants.
160
Midlife depression
Midlife in both men and women is characterized by a
steady decline in the production of androgens such as
dehydroepiandrosterone (DHEA) and androstenedione,
which are mostly of adrenal origin yet contribute up to
50% to circulating androgen levels (testosterone,dihy-
drotestosterone) in women.
155,161,162 Declining plasma lev-
els of testosterone in aging women may be less dramat-
ic due to continued secretion of testosterone by the
postmenopausal ovary.
163We examined the effects of the
adrenal androgen DHEA on mood in women with
midlife-onset depression in a double-blind,placebo-con-
trolled, crossover design study. Preliminary results are
consistent with previous studies by Wolkowitz et al
164 and
suggest the antidepressant efficacy of DHEA:DHEA,
but not placebo,significantly improved depression rat-
ings after 6 weeks of treatment
165 (Daly et al,unpublished
data).Plasma testosterone levels increased by approxi-
mately 30% after DHEA treatment (Smith et al,unpub-
lished data).However,baseline plasma levels of DHEA
or metabolites of DHEA (estradiol and testosterone)
and mood were not correlated,and the lack of correla-
tions between therapeutic response and baseline DHEA
levels emphasizes our inability to infer that midlife
depression in any way reflects a deficiency of reproduc-
tive hormones (Daly et al,personal communication).
Mood disorders in the context of medical illness
Several studies have suggested a potential role of hypo-
gonadism in the mood symptoms and low energy present
in some women with human immunodeficiency virus
(HIV) infection.
166-168Trials of DHEA in women and other
androgens such as testosterone in men with HIV have
reported mood improvements.
166,169,170 Although these
reports may suggest a psychotropic effect of gonadal
steroids in these subjects,the improved mood may also
reflect the anabolic effects of these steroids. Improved
muscle strength and weight changes in these subjects may
improve energy level and,therefore,indirectly improve
mood.
170,171
Potential mechanisms of antidepressant
action of gonadal steroids
Several mechanisms may underlie the antidepressant
effects of reproductive therapies in women.First,gonadal
steroid supplements may correct a pathological deficien-
cy of a particular gonadal steroid.However,in the major-
ity of studies where gonadal steroids have been reported
to be effective,the condition is neither associated with a
particular abnormality of reproductive hormones nor are
levels of reproductive hormones predictive of subsequent
response to the therapeutic intervention. Nonetheless,
local tissue metabolism of gonadal steroids (eg,aromat-
ization of androgens) may produce a wide range of
gonadal steroid levels within specific tissues.Thus,local
and tissue-specific “relative”deficiencies of reproductive
hormones could exist and cause symptoms, but not be
identified by simply measuring plasma hormone levels.
Second, studies of the effects of ERT in osteoporosis
172
suggest the presence of a threshold of circulating estra-
diol above which therapeutic effects are observed, and
it is possible that a similar phenomenon (ie, critical
threshold) is operational in reproductive hormone–related
effects on mood. For example, in women with premen-
strual syndrome, a threshold of gonadal steroid levels
may exist above which mood instability occurs, and,
therefore, ovarian suppression with low level gonadal
steroid replacement may produce mood stability.
Additionally, there may be a critical threshold of estra-
diol or DHEA levels below which symptoms develop in
some women, and the replacement of these hormones
may elevate hormone levels sufficiently to produce a
mood-enhancing effect.Third,the rate of change in hor-
mone level may convey information and trigger mood
changes in women who have a differential sensitivity to
increasing (eg,PMS) or decreasing (eg,perimenopausal
or postpartum depression) levels of gonadal steroids.
Although basal hormone abnormalities do not charac-
terize most women with reproductive endocrine–related
mood disorders or classical mood disorders, diagnosis-
related differences in the rapidity of the decline ingonadal steroids during the postpartum or during the
perimenopause may contribute to the onset of mood
symptoms, a phenomenon that would not readily be
identified in cross-sectional studies. Gonadal steroid
replacement, therefore, could attenuate the rate of
change of gonadal steroids in these subjects and prevent
the occurrence of depression. Finally, it is possible that
a direct psychotropic effect of gonadal steroids may be
involved in their antidepressant efficacy. For example,
the efficacy of estradiol in perimenopausal depres-
sion
129,130 and reports (in some
156,157 but not all
158 studies) of
estrogen augmenting the therapeutic efficacy of SSRIs
suggest that estrogen may be acting pharmacologically,
like other antidepressants, to alter the function of the
central serotonin system.
173-175 Roca et al
176 have attempted
to identify a possible role of serotonin in the antide-
pressant efficacy of ERT in perimenopause-related
depression by employing the serotonin receptor antag-
onist metergoline. Perimenopausal depressed women
who had previously demonstrated a remission of their
mood symptoms on estradiol but not placebo were
placed on open estrogen treatment. Subjects were
administered metergoline or active placebo (benadryl)
in a double-blind, crossover design. Depressive symp-
toms but not hot flushes returned 24 hours after meter-
goline administration.These changes in symptoms were
not seen after placebo administration.These data sug-
gest that the psychotropic effects of estradiol in depres-
sion may be mediated through the serotonin receptor
subtypes antagonized by metergoline.The specific mech-
anisms underlying the therapeutic effects of reproduc-
tive therapies await the development of more specific
antagonists of receptors for both gonadal steroids and
neural systems such as the serotonin system.
Future directions
Advances in reproductive therapies for non–mood-
related conditions should further the development of
compounds whose pharmacologic actions are more spe-
cific and clearly defined and, therefore, will assist in
efforts to determine the mechanisms of efficacy of repro-
ductive hormones and their analogues in mood disorders
in women.Receptor antagonists are available currently
for each of the members of the family of steroid recep-
tors. However, efforts to identify and characterize the
mechanisms mediating the antidepressant response to
gonadal steroids require the development of gonadal
steroid receptor antagonists that reliably cross the
blood–brain barrier and display receptor-subtype and
brain-region specificity.Such compounds,for example,
will facilitate investigations into the roles of estrogen
receptors alpha and beta in the psychotropic actions of
estradiol.Indeed,recent work by Krezel et al
177 suggest
that estrogen receptor beta,but not alpha,plays a promi-
nent role in anxiety in rodents.Selective gonadal steroid
receptor modulators are being developed for each of the
gonadal steroid receptors,estrogen alpha and beta,prog-
esterone,and androgen,and will provide a new genera-
tion of hormonal therapies that could provide more
selective and targeted therapeutic effects.For example,
beta-estrogen receptor–selective ligands may have dif-
fering effects on cognition than estradiol given the rela-
tively higher concentration of estrogen receptor beta
than alpha in the hippocampus.
178,179Additionally,selec-
tive androgen receptor modulators (SARMs),
180 selective
estrogen receptor modulators (SERMs),
181 and selective
progesterone receptor modulators (SPRMs)
182,183 may dis-
play a more acceptable profile of long-term side effects
(eg,lack of activity of SARMs at the prostate
180) and per-
mit their use on a more chronic basis.
A potential advantage of reproductive hormonal thera-
pies over conventional antidepressants is suggested by
studies reporting the medical sequelae of depression
including disorders of metabolism, the musculoskeletal
system, and the cardiovascular system.
184,185 Given the
strong association of some of these disorders with defi-
cient or abnormal reproductive endocrine activity,
33,186-188
reproductive therapies of depression might prevent or
reverse some of the medical sequelae in addition to
improving mood. Finally, effects of reproductive thera-
pies on the vascular endothelium and local blood flow
may contribute to therapeutic effects of these com-
pounds (eg, estradiol or DHEA) in certain conditions
where deficits in the vascular system are thought to
mediate the primary mood problem, such as in the vas-
cular depressions described in the late-onset mood dis-
orders.
189
Conclusions
Compared with studies performed in the 1800s and to
some extent the 1940s and 1950s,recent trials of repro-
ductive endocrine therapies in mood disorders in women
have employed more selective pharmacologic com-
pounds,more rigorous study designs,and in some studies
218
Clinical researchmore homogeneous patient samples.Despite improved
methodologies, the effects of gonadal steroids on 
mood regulation remain inconsistently demonstrated.
However, there are compelling data supporting a role
for gonadal steroids (and reproductive endocrine mod-
ulators) in the treatment of depression in women.
Future studies should be directed to better identify
both the clinical predictors and the physiological mech-
anisms of the psychotropic efficacy of reproductive
therapies. ❏
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Tratamientos con hormonas de la 
reproducción para los trastornos 
del ánimo en las mujeres
Desde hace más de un siglo en la medicina ha exis-
tido la visión que la función reproductora tanto en
los hombres como en las mujeres está íntimamente
relacionada con la regulación del ánimo. El siglo
XIX fue testigo de una proliferación de informes
médicos en que se documentaban los beneficios
sobre el ánimo y la conducta luego de manipular
médica o quirúrgicamente la función reproductora
de las mujeres. Más recientemente, los resultados
de diversos estudios sugieren que los esteroides
gonadales regulan el ánimo en algunas mujeres. Es
así como existe un considerable interés en el poten-
cial papel de las terapias con hormonas de la repro-
ducción en el manejo de la enfermedad depresiva,
incluyendo tanto los trastornos del ánimo clásicos
como aquéllos relacionados con la endocrinología
de la reproducción. Se requiere de futuros estudios
para determinar predictores de respuesta a terapias
hormonales comparadas con agentes antidepresi-
vos tradicionales y también para caracterizar la
seguridad a largo plazo y los beneficios de estas
terapias.
Traitements hormonaux de la fonction
reproductrice utilisés pour les troubles 
de l’humeur chez la femme
Depuis plus d’un siècle, la médecine a pensé que la
fonction reproductrice, aussi bien chez l’homme
que chez la femme, était intimement liée avec la
régulation de l’humeur. Le XIX
e siècle fut le témoin
d’une pléthore de textes affirmant les effets béné-
fiques sur l’humeur et le comportement de mani-
pulations médicales ou chirurgicales de la fonction
reproductrice féminine. Plus récemment, les résul-
tats de plusieurs études ont suggéré que les sté-
roïdes gonadiques régulaient l’humeur de certaines
femmes. Le rôle potentiel des traitements de la
fonction reproductrice présente ainsi un intérêt
considérable dans la prise en charge de la maladie
dépressive, tant sur le plan des troubles de l’hu-
meur classiques que de ceux liés à l’endocrinologie
de la reproduction. Les études à venir devront
déterminer les facteurs prédictifs des réponses aux
thérapies hormonales comparés aux traitements
antidépresseurs classiques et définir la tolérance à
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